西部证券股份有限公司 关于重庆山外山血液净化技术股份有限公司 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》和《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有 关法律、法规的规定，西部证券股份有限公司（以下简称"保荐人"）作为重庆 山外山血液净化技术股份有限公司（以下简称"山外山"、"公司"）持续督导工 作的保荐人，负责山外山上市后的持续督导工作，并出具本持续督导跟踪报告。 一、持续督导工作情况 序号 工作内容 持续督导情况 保荐人己建立健全并有效执行了 建立健全并有效执行持续督导工作制度，并针 对具体的持续督导工作制定相应的工作计划 工作计划 根据中国证监会相关规定，在持续督导工作开 保荐人己与山外山签订《保荐协 始前，与上市公司签署持续督导协议，明确双 议》，该协议明确了双方在持续督 方在持续督导期间的权利义务，并报上海证券 导期间的权利和义务，并报上海 交易所备案 证券交易所备案 保荐人通过日常沟通、定期或不 通过日常沟通、定期回访、现场检查、尽职调 定期回访、现场检查等方式，了解 查等方式开展持续督导工作 山外山业务情况，对山外山开展 持续督导工作 持续督 ...

Group 1 - Kangfang Biotech's PD-1/CTLA-4 bispecific antibody KAITENI® has received approval for a new indication in the treatment of cervical cancer, marking the third indication for this drug [1] - Tianyi Medical has obtained product registration certificates for single-use continuous renal replacement therapy tubing and single-use hemodialysis tubing, both sterilized with ethylene oxide [2] - Jincheng Pharmaceutical's posaconazole enteric-coated tablets and injectable cefoperazone sodium have been approved, enhancing the company's competitiveness in the antifungal and anti-infection sectors [3] Group 2 - Prolo Pharma has received approval for the raw material drug succinate desvenlafaxine, expanding its product pipeline in the antidepressant treatment field [4] - Wantai Biological Pharmacy's first domestically produced nine-valent HPV vaccine has been approved, with approximately 1 billion yuan invested in research and development as of May 2025 [5] - Yuheng Pharmaceutical's subsidiary has signed a market promotion service agreement with Eisai (China) Pharmaceutical for the exclusive promotion of mecobalamin injection, which is used for peripheral neuropathy and vitamin B12 deficiency-related anemia [6]